Compare Johnson & Johnson (JNJ) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs UnitedHealth Group Inc — how do they compare? Johnson & Johnson trades at $260.87 (market cap $626.09B), while UnitedHealth Group Inc trades at $405.69 (market cap $361.00B). The key difference: Johnson & Johnson is the larger of the two by market cap, and UnitedHealth Group Inc pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| JNJ | UNH | |
|---|---|---|
Market Cap | $626.09B | $361.00B |
Volume | 6,156,228 | — |
Sector | Health | Health |
52-Week High | $267.24 | $436.35 |
52-Week Low | $174.16 | $259.02 |
Enterprise Value | $654.37B | $402.86B |
Dividend Yield | 2.06% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
UnitedHealth Group (UNH) trades at $402.19, down 1.6% with bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats with Q1 2026 EPS of $7.23 beating estimates by 12%. Revenue grew to $447.57 billion in 2025, though net margins compressed to 2.69%. Analyst consensus remains strongly bullish with 83% buy ratings and a $476.50 price target representing 18% upside potential.
UNH presents a compelling long-term investment opportunity driven by aging demographics and healthcare digitization, but faces near-term headwinds from regulatory scrutiny and margin pressure. The stock's current valuation at 25.85x P/E appears reasonable given growth prospects, though investors should monitor legal challenges and Medicare reimbursement trends that could impact profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
